Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKS NASDAQ:CLDX NASDAQ:HALO NASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$54.58$41.30$25.17▼$55.28$9.10B0.342.65 million shs1.65 million shsCLDXCelldex Therapeutics$38.37$32.31$19.72▼$39.16$3.01B0.91.25 million shs876,731 shsHALOHalozyme Therapeutics$79.45$69.18$53.33▼$82.22$9.42B0.841.78 million shs1.56 million shsRGENRepligen$142.40$123.48$100.99▼$175.77$8.03B1.061.11 million shs981,628 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes+5.53%+3.31%+32.09%+56.66%+88.21%CLDXCelldex Therapeutics+4.32%+12.56%+32.77%+23.54%+73.54%HALOHalozyme Therapeutics+3.17%+9.38%+19.87%+23.20%+47.57%RGENRepligen+2.45%-1.95%+17.56%+20.90%+12.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$54.58$41.30$25.17▼$55.28$9.10B0.342.65 million shs1.65 million shsCLDXCelldex Therapeutics$38.37$32.31$19.72▼$39.16$3.01B0.91.25 million shs876,731 shsHALOHalozyme Therapeutics$79.45$69.18$53.33▼$82.22$9.42B0.841.78 million shs1.56 million shsRGENRepligen$142.40$123.48$100.99▼$175.77$8.03B1.061.11 million shs981,628 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes+5.53%+3.31%+32.09%+56.66%+88.21%CLDXCelldex Therapeutics+4.32%+12.56%+32.77%+23.54%+73.54%HALOHalozyme Therapeutics+3.17%+9.38%+19.87%+23.20%+47.57%RGENRepligen+2.45%-1.95%+17.56%+20.90%+12.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.72Moderate Buy$49.63-9.08% DownsideCLDXCelldex Therapeutics 2.82Moderate Buy$49.3028.49% UpsideHALOHalozyme Therapeutics 2.54Moderate Buy$81.602.71% UpsideRGENRepligen 2.88Moderate Buy$164.6415.62% UpsideCurrent Analyst Ratings BreakdownLatest CLDX, ALKS, HALO, and RGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2026ALKSAlkermes MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$53.00 ➝ $65.006/29/2026ALKSAlkermes Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$44.00 ➝ $65.006/29/2026ALKSAlkermes Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform6/26/2026RGENRepligen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)6/24/2026ALKSAlkermes Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$54.00 ➝ $61.006/22/2026ALKSAlkermes TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $50.006/18/2026ALKSAlkermes HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral6/18/2026ALKSAlkermes Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $54.006/16/2026HALOHalozyme Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/15/2026CLDXCelldex Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.006/10/2026CLDXCelldex Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $45.00(Data available from 7/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.48B6.16$1.77 per share30.89$11.02 per share4.95CLDXCelldex Therapeutics$865K3,481.78N/AN/A$7.93 per share4.84HALOHalozyme Therapeutics$1.40B6.75$4.92 per share16.14$0.42 per share189.17RGENRepligen$738.26M10.88$3.50 per share40.68$37.42 per share3.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$241.66M$0.9060.65188.21N/A9.78%9.26%5.66%7/28/2026 (Estimated)CLDXCelldex Therapeutics-$258.76M-$4.26N/AN/AN/AN/A-50.72%-46.59%8/6/2026 (Estimated)HALOHalozyme Therapeutics$316.89M$2.7828.588.650.3223.13%187.91%21.92%8/4/2026 (Estimated)RGENRepligen$48.89M$0.90158.2258.602.686.73%4.88%3.48%8/4/2026 (Estimated)Latest CLDX, ALKS, HALO, and RGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/28/2026Q2 2026ALKSAlkermes-$0.04N/AN/AN/A$459.62 millionN/A5/11/2026Q1 2026HALOHalozyme Therapeutics$1.54$1.60+$0.06$1.22$358.60 million$376.71 million5/7/2026Q1 2026CLDXCelldex Therapeutics-$1.1472-$1.18-$0.0328-$1.18$0.80 million$0.02 million5/5/2026Q1 2026RGENRepligen$0.38$0.48+$0.10$0.15$192.05 million$194.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermes0.852.271.70CLDXCelldex TherapeuticsN/A8.928.92HALOHalozyme Therapeutics8.812.762.33RGENRepligen0.269.207.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%CLDXCelldex TherapeuticsN/AHALOHalozyme Therapeutics97.79%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.59%CLDXCelldex Therapeutics5.20%HALOHalozyme Therapeutics2.50%RGENRepligen0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes2,050166.68 million159.03 millionOptionableCLDXCelldex Therapeutics15078.49 million74.41 millionOptionableHALOHalozyme Therapeutics390118.61 million115.65 millionOptionableRGENRepligen2,00056.41 million56.07 millionOptionableCLDX, ALKS, HALO, and RGEN HeadlinesRecent News About These CompaniesHere’s Why Repligen Corp. (RGEN) Fell 28% in Q1June 30 at 10:51 AM | finance.yahoo.comRepligen (NASDAQ:RGEN) CFO Sells $106,285.00 in StockJune 29, 2026 | americanbankingnews.comInsider Selling: Repligen (NASDAQ:RGEN) CFO Sells 733 Shares of StockJune 27, 2026 | insidertrades.comWasatch Advisors LP Purchases New Position in Repligen Corporation $RGENJune 27, 2026 | marketbeat.com2 high-flying stocks on our watchlist and 1 we find riskyJune 25, 2026 | msn.comRepligen jumps as investors revisit strong Q1 results and bioprocessing recovery outlookJune 24, 2026 | quiverquant.comQRepligen Corporation (RGEN) Dropped Following the Earnings ReleaseJune 24, 2026 | insidermonkey.comRepligen (RGEN) Dropped Following the Earnings ReleaseJune 24, 2026 | finance.yahoo.comRepligen Corp (RGEN) Shares Fall 4.1% -- What GF Score of 83 Tells InvestorsJune 22, 2026 | gurufocus.com2 Profitable Stocks on Our Watchlist and 1 Facing ChallengesJune 19, 2026 | finance.yahoo.comRepligen Corporation (RGEN) Slid on Softened Enthusiasm for Life Sciences ToolsJune 19, 2026 | finance.yahoo.comRBC Capital Resumes Repligen Corp (RGEN) Stock Coverage. Here’s Its ViewJune 12, 2026 | insidermonkey.comRepligen Corp (RGEN) Shares Surge 3.8% -- What GF Score of 83 Tells InvestorsJune 9, 2026 | gurufocus.comRepligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound?June 4, 2026 | zacks.comRepligen Corporation (RGEN) Presents at 46th Annual William Blair Growth Stock Conference - SlideshowJune 4, 2026 | seekingalpha.comRepligen Corporation (RGEN) Presents at 46th Annual William Blair Growth Stock Conference TranscriptJune 3, 2026 | seekingalpha.comRepligen Has A Cleaner Recovery Angle, But With High ValuationMay 31, 2026 | seekingalpha.comRepligen Corp (RGEN) Stock Up 8.4% and Still Undervalued -- GF Score: 79/100May 28, 2026 | gurufocus.comGuggenheim Reaffirms Their Hold Rating on Repligen (RGEN)May 25, 2026 | theglobeandmail.comRepligen Corporation to Present at William Blair 46th Annual Growth Stock ConferenceMay 22, 2026 | globenewswire.comRepligen Announces Publication of the Company’s 2025 Corporate Sustainability ReportMay 20, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026Why Wall Street Still Sees Massive Upside for AeroVironment StockBy Thomas Hughes | June 30, 2026SMRs Spark a Chain Reaction for Nano NuclearBy Jeffrey Neal Johnson | July 2, 2026CLDX, ALKS, HALO, and RGEN Company DescriptionsAlkermes NASDAQ:ALKS$54.58 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$53.52 -1.06 (-1.93%) As of 07/2/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Celldex Therapeutics NASDAQ:CLDX$38.37 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$38.32 -0.05 (-0.14%) As of 07/2/2026 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Halozyme Therapeutics NASDAQ:HALO$79.45 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$77.35 -2.10 (-2.65%) As of 07/2/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Repligen NASDAQ:RGEN$142.40 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$143.00 +0.60 (+0.42%) As of 07/2/2026 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus Why Kroger's Giant Eagle Deal Could Change Everything SMRs Spark a Chain Reaction for Nano Nuclear Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
